Jaguar Health, Inc. (JAGX): debt financing — Jaguar Health extends note maturity to July 2025, reduces royalty balance by $1.09M via stock

On January 29, 2025, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary ("Napo" and together with the Company, the "Borrower"), entered into an amendment (the "Note Amendment") with Streeterville Capital, LLC ("Streeterville") to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the "Note") issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date (as amended, the "Note Purchase Agreement"). Pursuant to Note Amendment, the maturity date of the Note is extended to July 20, 2025.